|
Rowan Chapman joined MDV in 2001 to focus on life science investments. Her interests lie in the translation of complex data and technology to innovative products that impact drug and biofuel discovery, personalized medicine and healthcare decision making. Leveraging her business and technical experience as well as industry relationships she partners closely with entrepreneurs to help develop successful businesses. She partners with entrepreneurs in a "hands on" role to help get companies started and financed.
Rowan is a board member of MLC Dx and a board observer at Artemis Health, Pacific Biosciences, Adamas Pharmaceuticals, ParAllele BioScience (acquired by Affymetrix) and Tethys Biosciences. Rowan is also a member of the Personalized Medicine Coalition.
Prior to joining MDV Rowan held the position of director of business development at Rosetta Inpharmatics (acquired by Merck) where she established collaborative partnerships with organizations in the pharmaceutical, agricultural and biotech fields as well as among various research institutions. Previously, Rowan held the position of marketing manager at Incyte Genomics.
Rowan holds a Ph.D. in cellular and molecular biology from the MRC Laboratory of Molecular Biology in Cambridge University, UK where she also earned a bachelor's degree with first class honors in Biochemistry. She served postdoctoral fellowships at the University of California, San Francisco, as well as at the MRC-Laboratory of Molecular Biology at Cambridge. Prior to her work in industry, she authored or co-authored more than a dozen articles and patents.
< Back to Team Main
|
